Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Taiwan J Obstet Gynecol. 2009 Dec;48(4):375-9. doi: 10.1016/S1028-4559(09)60326-0.
To compare the efficacy of two vaginal progesterone formulations, Crinone gel and Utrogestan capsules, for luteal phase support in blastocyst stage embryo transfers.
We analyzed 460 consecutive cycles in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-blastocyst transfer (BT) treatment at our institution between January 2004 and December 2007. Patients applied either Crinone 8% vaginal gel (90 mg, once daily) or Utrogestan vaginal capsules (200 mg, four times daily) for luteal supplementation. Progesterone was administered from the day of oocyte retrieval to pregnancy confirmation. Clinical pregnancy and implantation rates were the main outcome measures.
The clinical pregnancy rate (58.7% vs. 44.3%) and implantation rate (32.04% vs. 23.89%) were significantly higher in the Crinone group compared with the Utrogestan group after IVF/ICSI-BT treatment.
Luteal phase support with Crinone 8% vaginal gel (90 mg daily) resulted in better clinical pregnancy and implantation rates than Utrogestan vaginal capsules (200 mg, four times daily) in IVF/ICSI-BT cycles.
比较两种阴道黄体酮制剂——Crinone 凝胶和 Utrogestan 胶囊在囊胚期胚胎移植中黄体支持的疗效。
我们分析了 2004 年 1 月至 2007 年 12 月在我院接受体外受精/卵胞浆内单精子注射（IVF/ICSI）-囊胚移植（BT）治疗的 460 例连续周期。患者应用 Crinone 8%阴道凝胶（90mg，每日一次）或 Utrogestan 阴道胶囊（200mg，每日四次）进行黄体补充。从取卵日开始给予孕激素至妊娠确认。主要观察指标为临床妊娠率和着床率。
与 Utrogestan 组相比，Crinone 组在 IVF/ICSI-BT 治疗后临床妊娠率（58.7% vs. 44.3%）和着床率（32.04% vs. 23.89%）显著提高。
在 IVF/ICSI-BT 周期中，Crinone 8%阴道凝胶（每日 90mg）黄体支持的临床妊娠率和着床率优于 Utrogestan 阴道胶囊（每日 200mg，每日四次）。
